Last reviewed · How we verify

NCT05826795

Cost-effectiveness of EGDT Using FloTrac/EV1000

Status unknown Last updated 24 April 2023
What this trial tests

trial testing Early goal-directed therapy (EGDT) in Coronary Artery Disease in 60 participants. Status unknown.

Timeline
1 April 2023
Primary endpoint
1 May 2023
10 May 2023

Quick facts

Lead sponsorKhon Kaen University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment60
Start date1 April 2023
Primary completion1 May 2023
Estimated completion10 May 2023
Sites2 locations across Thailand

Drugs / interventions tested

Conditions studied

Sponsor

Khon Kaen University

Who can join

Adults 18 to 85, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Coronary artery bypass graft (CABG) with cardiopulmonary bypass (CPB) is a high-risk surgery with significant morbidity that results in a prolonged stay in the intensive care unit (ICU) at an increased cost. Early goal-directed therapy (EGDT) using the FloTrac/EV1000 platform improved outcomes in these patients with shorter ICU stay but with extra cost for a FloTrac transducer. The objective of this study is to assess the cost-effectiveness of implementing the FloTrac/EV1000 in these patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other Khon Kaen University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05826795.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing